IT STARTS WITH IMPLEMENTATION
UK Implementation Case Studies
Three case studies outlining service delivery models for implementing Vocabria (cabotegravir) and Rekambys (rilpirvine) long-acting injectables effectively into NHS services.* Including top tips from healthcare care professionals involved in the set-up and running of these services. Please refer to SmPCs before administering.[1,2]
PM-GB-CBR-WCNT-240007 | March 2024
*The HCPs interviewed have consented to ViiV Healthcare utilising their case study and have received remuneration from ViiV Healthcare for their time.
REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-240003 | February 2024
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
